Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant effect on estrogen receptor availability by FES-PET in metastatic breast cancer
NL-OMON39073Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fulvestrant in breast cancer, sponsored by University Medical Center Groningen. Started May 2011; status: active, not recruiting.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON39073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39073.